{"id":"defibrotide-injection","brandName":"Defibrotide Injection","genericName":"Defibrotide Injection","companyId":"irccs-san-raffaele","companyName":"IRCCS San Raffaele","phase":"phase_2","status":"active","modality":"Small molecule","aliases":[],"developmentCodes":[],"firstApprovalDate":null,"firstApprovalCountry":null,"aiSummary":"Defibrotide Injection, developed by IRCCS San Raffaele, is a promising treatment for various conditions including thrombotic microangiopathy and severe COVID-19. Currently in multiple Phase 2 trials, it shows potential in preventing and treating respiratory distress and cytokine release syndrome. The drug has no FDA label but is actively being studied for its safety and efficacy.","enrichmentLevel":3,"visitCount":0,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Defibrotide is a mixture of single-stranded oligonucleotides that inhibit the activity of phosphodiesterase, leading to an increase in cyclic AMP levels and a subsequent decrease in platelet activation.","oneSentence":"Phosphodiesterase inhibitor","_ai_confidence":"medium"},"administration":{},"safety":{"commonSideEffects":[{"rate":"null","effect":"Nausea"},{"rate":"null","effect":"Vomiting"},{"rate":"null","effect":"Diarrhea"}]},"trials":[],"indications":{"approved":[{"name":"Hepatic Veno-Occlusive Disease"}]},"commercial":null,"patents":[],"timeline":[],"rwe":[],"competitors":[],"ownershipHistory":[],"trialDetails":[],"genericFilers":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"labelChanges":[],"nice":null,"revenue":null,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":false,"score":3}}